Home/Pipeline/CECSi Cell Therapy

CECSi Cell Therapy

Bullous Keratopathy

Phase 1/Phase 1 equivalentActive

Key Facts

Indication
Bullous Keratopathy
Phase
Phase 1/Phase 1 equivalent
Status
Active
Company

About Cellusion

Developing iPSC-derived corneal endothelial cell injection therapy to address the global shortage of donor corneas for transplants.

View full company profile

Therapeutic Areas